Drug Approval | March 27, 2024
FDA approves Merck’s WINREVAIR for treatment of pulmonary arterial hypertension
WINREVAIR is a breakthrough biologic for this rare, progressive disease
WINREVAIR is a breakthrough biologic for this rare, progressive disease
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
Elegen is the only DNA manufacturer delivering the unique combination of complexity, length and NGS-verified accuracy within days
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Additional capacity broadens Grace’s fine chemical capabilities for API production
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
The drug will target specific genetic mutations prevalent in certain types of cancers
It is the first autotaxin inhibitor to be investigated in cancer patients
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
Subscribe To Our Newsletter & Stay Updated
